title: Spectral-Domain Optical Coherence Tomography of Subretinal Hyperreflective Exudation in Myopic Choroidal Neovascularization.
abstract: OBJECTIVE
  To study the effect of anti-vascular endothelial growth factor (VEGF) therapy on subretinal hyperreflective exudation detected by spectral-domain optical coherence tomography (SD OCT) in myopic choroidal neovascularization (CNV).
  
  
  METHODS
  Retrospective consecutive observational cohort study.
  
  
  METHODS
  Thirty-one eyes of 31 consecutive highly myopic patients with CNV and showing a subretinal hyperreflective exudation on SD OCT were included. Morphologic changes were assessed before and after anti-VEGF therapy, based on the subretinal hyperreflective exudation thickness, retinal thickness at the level of the CNV, and central macular thickness.
  
  
  RESULTS
  After anti-VEGF treatment (mean follow-up of 1.9 ± 0.8 months, mean number of injections 1.8 ± 0.6), the subretinal hyperreflective exudation regressed completely in 29 of 31 eyes (93.5%) and partially in 2 of 31 eyes (6.5%). Mean subretinal hyperreflective exudation thickness, mean retinal thickness at the level of the CNV, and mean central macular thickness significantly decreased from 102 ± 50 μm to 2.6 ± 10.2 μm (P < .0001), from 419 ± 99 μm to 312 ± 64 μm (P < .0001), and from 361 ± 69 μm to 326 ± 72 μm (P = .0008), respectively.
  
  
  CONCLUSIONS
  The subretinal hyperreflective exudation was an SD OCT finding that correlated with signs of active myopic CNV (either subretinal fluid/intraretinal cysts on SD OCT or dye leakage on fluorescein angiography) and responded to treatment with anti-VEGF agents. The presence of a subretinal hyperreflective exudation on SD OCT could help in making decisions on the need to perform or not perform fluorescein angiography, and regarding treatment or retreatment.
authors.affiliation: Centre Hospitalier Intercommunal de Créteil, CRC, Paris Est Créteil University, Créteil, France.
authors.forename: Elsa
authors.initials: E
authors.lastname: Bruyère
authors.affiliation: Centre Hospitalier Intercommunal de Créteil, CRC, Paris Est Créteil University, Créteil, France.
authors.forename: Violaine
authors.initials: V
authors.lastname: Caillaux
authors.affiliation: Centre Hospitalier Intercommunal de Créteil, CRC, Paris Est Créteil University, Créteil, France.
authors.forename: Salomon Yves
authors.initials: SY
authors.lastname: Cohen
authors.affiliation: Centre Hospitalier Intercommunal de Créteil, CRC, Paris Est Créteil University, Créteil, France.
authors.forename: David
authors.initials: D
authors.lastname: Martiano
authors.affiliation: Centre Hospitalier Intercommunal de Créteil, CRC, Paris Est Créteil University, Créteil, France.
authors.forename: Raphaelle
authors.initials: R
authors.lastname: Ores
authors.affiliation: Centre Hospitalier Intercommunal de Créteil, CRC, Paris Est Créteil University, Créteil, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Puche
authors.affiliation: Centre Hospitalier Intercommunal de Créteil, CRC, Paris Est Créteil University, Créteil, France. Electronic address: eric.souied@chicreteil.fr.
authors.forename: Eric H
authors.initials: EH
authors.lastname: Souied
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001813:Blood-Retinal Barrier; D002199:Capillary Permeability; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D012189:Retrospective Studies; D058471:Subretinal Fluid / Q000502:physiology*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A